How nanomedicine contributes to better cancer diagnostic and therapy

How nanomedicine contributes to better cancer diagnostic and therapy           

(Nanowerk News) In the framework of the World Cancer  Day, the European Technology Platform of Nanomedicine (ETPN) and its partners  will organize a European event on February the 1st on “How nanomedicine  contributes to better cancer diagnostic and therapy”. Similar and simultaneous  events will be organized in France and Portugal, highlighting the importance of  nanomedicine research for cancer on the European level.

Radiotherapy, chemotherapy and surgery are part of the  therapeutic arsenal for patients with cancer. New technologies associated with  nanoparticles could provide more effective solutions to personalize diagnoses  and treat these diseases, while improving targeted drug delivery and reducing  side effects and collateral damages on the body. These breakthrough therapies  based on nanomedicine are already a reality with concrete results, 60  nano-products on the market and more than 70 in the pipeline. Nanomedicine can  go further in bringing new therapeutic mode of action into cells. For instance,  nanoparticles can already be injected into the tumor and then be activated to  produce a physical effect and destroy cancer cells locally.

In the press events across Europe, leading international  stakeholders in the field will introduce examples highlighting the key role of  nanomedicine for cancer therapy, diagnoses and imaging.

This year, these stakeholders across Europe who have already  confirmed are:

National Cancer organizations:

–  Canceropole CLARA (FR) – Comprehensive Cancer Center (Charité University Hospital) (DE) – Instituto Português de Oncologia do Porto (PT)

SMEs: Nanobiotix (FR)

Universities / Public laboratories:

– Thomas Jefferson University, Philadelphia (US) – CNRS / Paris 11 University (FR) – Ludwig-Maximilians University München (DE) – Aachen University Hospital (DE) – INL – International Iberian Nanotechnology Laboratory (Portugal-Spain) – Universidad de Santiago de Compostela (Spain) – University of Lisboa/ Faculty of Pharmacy (PT).

Leading local experts involved in the Berlin Press event:

Professor  Reinhold Schäfer, Head of the Laboratory of Molecular Tumor Pathology,  Comprehensive Cancer Center, Charité University Hospital, Berlin Bernd  Muehlenweg, Representative of the ETP Nanomedicine and of Nanobiotix,  Paris/Hamburg Dr  Manfred Ogris, Department of Pharmacy, Ludwig-Maximilians University München,  Munich Dr  Twan Lammers, Department of Experimental Molecular Imaging, Aachen University  Hospital, Aachen

This conference will give an overview on nanomedicine for  cancer: What are the key areas of research? What are the new methods of  diagnosis? What are the new treatments in development? What are the first  results? What are the products used every day? source:http://genesisnanotech.wordpress.com